Patrice P. Denefle
Keine laufenden Positionen mehr
Profil
Patrice P.
Denefle worked as the Chief Scientific Officer at Genethon and 4P-Pharma.
He also served as the Chief Scientific Officer at Centogene NV from 2021 to 2023.
Dr. Denefle completed his undergraduate degree at Université De Lille.
Ehemalige bekannte Positionen von Patrice P. Denefle
| Unternehmen | Position | Ende |
|---|---|---|
| CENTOGENE N.V. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2023 |
| 4P-Pharma | Technik-/Wissenschafts-/F&E-Leiter | - |
Genethon
 Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Patrice P. Denefle
| Université De Lille | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CENTOGENE N.V. | Commercial Services |
| Private Unternehmen | 2 |
|---|---|
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | Health Technology |
| 4P-Pharma | Commercial Services |
